DOI: 10.1210/endo.134.5.8156994 Arvat E et al
Standard AOD-9604 Dosing Protocol Typical Dosing Range: Standard Dose: 250-500 mcg per day Clinical Trial Dose: 1 mg (1,000 mcg) per day (most effective in studies) Conservative Start: 250 mcg per day for first week Maintenance Range: 500 mcg per day for sustained protocols Frequency: Once daily, typically before breakfast Timing Rationale: Morning fasted state maximizes fat oxidation potential Cycle Length: 12-24 weeks for body composition protocols Administration Route: Subcutaneous injection (abdomen, thigh, or upper arm) Reconstitution: Bacteriostatic water, standard peptide protocols Note: Clinical trials used oral formulations, but subcutaneous administration is more common in current use due to improved bioavailability
The package contains a custom formulation, visually appealing packaging, required regulatory documents, large-scale production capabilities, and expedited shipping
FDA-approved semaglutide products (Ozempic, Wegovy, Rybelsus) do not contain B12 and appear as clear, colorless solutions, similar to Mounjaro and Zepbound
Affected patients develop unilateral facial paralysis over one to three days with forehead involvement and no other neurologic abnormalities
